第 1 到 107 筆結果,共 107 筆。
公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 | |
---|---|---|---|---|---|---|---|
1 | 2023 | Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study | Qin, Shukui; Chan, Stephen L; Gu, Shanzhi; Bai, Yuxian; Ren, Zhenggang; Lin, Xiaoyan; Chen, Zhendong; Jia, Weidong; Jin, Yongdong; Guo, Yabing; Hu, Xiaohua; Meng, Zhiqiang; Liang, Jun; Cheng, Ying; Xiong, Jianping; Ren, Hong; Yang, Fang; Li, Wei; Chen, Yajin; Zeng, Yong; Sultanbaev, Alexander; Pazgan-Simon, Monika; Pisetska, Margaryta; Melisi, Davide; Ponomarenko, Dmitriy; Osypchuk, Yurii; Sinielnikov, Ivan; Yang, Tsai-Sheng; Liang, Xiao; Chen, Chunxia; Wang, Linna; ANN-LII CHENG ; Kaseb, Ahmed; Vogel, Arndt; CHIUN HSU | Lancet (London, England) | 83 | 16 | |
2 | 2023 | Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma | BANG-BIN CHEN ; PO-CHIN LIANG ; TIFFANY TING-FANG SHIH ; TSUNG-HAO LIU ; YING-CHUN SHEN ; LI-CHUN LU ; ZHONG-ZHE LIN ; CHIUN HSU ; CHIH-HUNG HSU ; ANN-LII CHENG ; YU-YUN SHAO | European radiology | 20 | 13 | |
3 | 2023 | Synergistic efficacy of telomerase-specific oncolytic adenoviral therapy and histone deacetylase inhibition in human hepatocellular carcinoma | ZHONG-ZHE LIN ; Hu, Mickey C-T; CHIUN HSU ; YAO-MING WU ; YEN-SHEN LU ; Ho, Ja-An Annie; Shiou-Hwei Yeh ; PEI-JER CHEN ; ANN-LII CHENG | Cancer letters | 1 | 1 | |
4 | 2023 | Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab | CHIUN HSU ; Ducreux, Michel; Zhu, Andrew X; Qin, Shukui; Ikeda, Masafumi; Kim, Tae-You; Galle, Peter R; Finn, Richard S; Chen, Ethan; Ma, Ning; Hu, Youyou; Li, Lindong; ANN-LII CHENG | Liver cancer | 1 | 0 | |
5 | 2022 | Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma | YU-YUN SHAO ; Chen, Pai-Sheng; LIANG-IN LIN ; Lee, Bin-Shyun; Ling, Andrew; ANN-LII CHENG ; CHIUN HSU ; DA-LIANG OU | British journal of cancer | 10 | 10 | |
6 | 2022 | Association of annexin A10 expression with poor prognosis of intrahepatic cholangiocarcinoma | YU-YUN SHAO ; HUNG-YANG KUO ; YUNG-MING JENG ; YAO-MING WU ; HSIU-PO WANG ; CHIUN HSU ; CHIH-HUNG HSU ; Hsu, Hey-Chi; ANN-LII CHENG ; ZHONG-ZHE LIN | BMC cancer | 3 | 3 | |
7 | 2021 | Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials | BANG-BIN CHEN ; ZHONG-ZHE LIN ; YU-YUN SHAO ; CHIUN HSU ; CHIH-HUNG HSU ; ANN-LII CHENG ; PO-CHIN LIANG ; TIFFANY TING-FANG SHIH | Cancers | 4 | 3 | |
8 | 2021 | Dynamic Contrast-Enhanced and Intravoxel Incoherent Motion MRI Biomarkers Are Correlated to Survival Outcome in Advanced Hepatocellular Carcinoma | BANG-BIN CHEN ; YU-YUN SHAO ; ZHONG-ZHE LIN ; CHIH-HUNG HSU ; ANN-LII CHENG ; CHIUN HSU ; PO-CHIN LIANG ; TIFFANY TING-FANG SHIH | Diagnostics (Basel, Switzerland) | 7 | 7 | |
9 | 2021 | Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy | YING-CHUN SHEN ; Yeh C.-P.; YUNG-MING JENG ; CHIUN HSU ; CHIH-HUNG HSU ; ZHONG-ZHE LIN ; YU-YUN SHAO ; LI-CHUN LU ; TSUNG-HAO LIU ; CHIEN-HUNG CHEN ; ANN-LII CHENG | Cancers | 2 | 2 | |
10 | 2021 | Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma | CHIA-LANG HSU ; DA-LIANG OU ; Bai L.-Y.; Chen C.-W.; Lin L.; Huang S.-F.; ANN-LII CHENG ; YUNG-MING JENG ; CHIUN HSU | Liver Cancer | 47 | 47 | |
11 | 2021 | Eg5 as a Prognostic Biomarker and Potential Therapeutic Target for Hepatocellular Carcinoma | YU-YUN SHAO ; Sun, Nai-Yun; YUNG-MING JENG ; YAO-MING WU ; CHIUN HSU ; CHIH-HUNG HSU ; Hsu, Hey-Chi; ANN-LII CHENG ; ZHONG-ZHE LIN | Cells | 3 | 2 | |
12 | 2021 | Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages | DA-LIANG OU ; Chen C.-W.; CHIA-LANG HSU ; Chung C.-H.; Feng Z.-R.; Lee B.-S.; ANN-LII CHENG ; Yang M.-H.; CHIUN HSU | Journal for ImmunoTherapy of Cancer | 68 | 44 | |
13 | 2020 | Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection | Tsou H.-H.; HUNG-CHIH YANG ; Hsiao C.-F; Hsiung C.A; Liu T.-W; Chuang M.-H; Wu H.-Y; Hsu Y.-T; Tsui C.-W; PEI-JER CHEN ; ANN-LII CHENG ; CHIUN HSU ; Taiwan Cooperative Oncology Group | Journal of the Formosan Medical Association | 8 | 8 | |
14 | 2020 | A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy | ZHONG-ZHE LIN ; BANG-BIN CHEN ; Hung, Yi-Ping; HUANG, PO-HSIANG ; Ying-Chun Shen ; YU-YUN SHAO ; CHIH-HUNG HSU ; ANN-LII CHENG ; Lee, Rheun-Chuan; Chao, Yee; CHIUN HSU | Oncologist | 12 | 10 | |
15 | 2020 | Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma | ANN-LII CHENG ; CHIUN HSU ; Chan S.L.; Choo S.-P.; Kudo M. | Journal of Hepatology | 306 | 267 | |
16 | 2020 | Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients | SHIH-HUNG YANG ; JHE-CYUAN GUO ; CHIUN HSU ; SUNG-HSIN KUO ; YU-WEN TIEN ; ANN-LII CHENG ; KUN-HUEI YEH | Journal of the Formosan Medical Association | 3 | 3 | |
17 | 2020 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO | Chen L.-T.; Martinelli E.; ANN-LII CHENG ; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; CHIUN HSU ; YING-CHUN SHEN ; Tabernero J.; Yen Y.; CHIH-HUNG HSU ; Yoshino T.; Douillard J.-Y. | Annals of Oncology | 128 | 112 | |
18 | 2019 | Considerations of heterogeneity in clinical trials for hepatocellular carcinoma | TSUNG-HAO LIU ; YU-YUN SHAO ; LI-CHUN LU ; Ying-Chun Shen ; CHIUN HSU ; ZHONG-ZHE LIN ; CHIH-HUNG HSU ; ANN-LII CHENG | Expert Review of Gastroenterology and Hepatology | 5 | 7 | |
19 | 2019 | Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma | DA-LIANG OU ; Lin, Yu-Yang; CHIA-LANG HSU ; Lin, Yin-Yao; Chen, Chia-Wei; Yu, Jhang-Sian; SHI-CHUEN MIAW ; PING-NING HSU ; ANN-LII CHENG ; CHIUN HSU | Liver cancer | 24 | 21 | |
20 | 2019 | Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma | ZHONG-ZHE LIN ; CHIUN HSU ; YUNG-MING JENG ; Hu F.-C.; Pan H.-W.; YAO-MING WU ; Hsu H.-C.; ANN-LII CHENG | Liver International | 18 | 18 | |
21 | 2019 | Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma | LI-CHUN LU ; CHIUN HSU ; YU-YUN SHAO ; Chao Y.; Yen C.-J.; I-LUN SHIH ; Hung Y.-P.; Chang C.-J.; Ying-Chun Shen ; JHE-CYUAN GUO ; TSUNG-HAO LIU ; CHIH-HUNG HSU ; ANN-LII CHENG | Liver Cancer | 46 | 44 | |
22 | 2019 | Early alpha‐foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma | YU-YUN SHAO ; TSUNG-HAO LIU ; CHIUN HSU ; LI-CHUN LU ; YING-CHUN SHEN ; ZHONG-ZHE LIN ; ANN-LII CHENG ; CHIH-HUNG HSU | Liver International | 58 | 58 | |
23 | 2018 | Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan | Wang, CK; MING-CHIH HO ; Su C.-W.; Wang T.-E.; Dai C.-Y.; CHIEN-HUNG CHEN ; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; PO-HUANG LEE ; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Lin S.-M.; GUAN-TARN HUANG ; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; PO-CHIN LIANG ; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; ANN-LII CHENG ; CHIUN HSU ; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; CHIA-HSIEN CHENG ; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; YEN-HSUAN NI ; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group; Surveillance group; Diagnosis group; Staging group; Surgery group; TACE/TARE/HAI group; Target therapy/systemic therapy group; Radiotherapy group; Prevention group; Drafting group | Journal of the Formosan Medical Association = Taiwan yi zhi | 90 | 87 | |
24 | 2018 | Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection | HUNG-CHIH YANG ; Tsou H.-H; Pei S.-N; Chang C.-S; Chen J.-H; MING YAO ; Lin S.-J; Lin J; Yuan Q; Xia N; Liu T.-W; PEI-JER CHEN ; ANN-LII CHENG ; CHIUN HSU ; Taiwan Cooperative Oncology Group | Journal of Hepatology | 69 | 58 | |
25 | 2018 | Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy | Lin Y.-Y.; CHING-TING TAN ; Chen C.-W.; DA-LIANG OU ; ANN-LII CHENG ; CHIUN HSU | Seminars in Liver Disease | 62 | 53 | |
26 | 2017 | Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy | YU-YUN SHAO ; BANG-BIN CHEN ; DA-LIANG OU ; ZHONG-ZHE LIN ; CHIH-HUNG HSU ; Wang, M. J.; ANN-LII CHENG ; CHIUN HSU | Alimentary Pharmacology and Therapeutics | 10 | 8 | |
27 | 2017 | Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma | BANG-BIN CHEN ; CHAO-YU HSU ; CHIH-WEI YU ; PO-CHIN LIANG ; CHIUN HSU ; CHIH-HUNG HSU ; ANN-LII CHENG ; TIFFANY TING-FANG SHIH | European Radiology | 15 | 17 | |
28 | 2016 | Tumor heterogeneity in hepatocellular carcinoma: Facing the challenges | LI-CHUN LU ; CHIH-HUNG HSU ; CHIUN HSU ; ANN-LII CHENG | Liver Cancer | 95 | 98 | |
29 | 2016 | Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer | SHIH-HUNG YANG ; TING-CHUN KUO ; Wu H.; JHE-CYUAN GUO ; CHIUN HSU ; CHIH-HUNG HSU ; YU-WEN TIEN ; KUN-HUEI YEH ; ANN-LII CHENG ; SUNG-HSIN KUO | World Journal of Gastroenterology | 24 | 25 | |
30 | 2016 | Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy | BANG-BIN CHEN ; CHAO-YU HSU ; CHIH-WEI YU ; PO-CHIN LIANG ; CHIUN HSU ; CHIH-HUNG HSU ; ANN-LII CHENG ; TIFFANY TING-FANG SHIH | Radiology | 27 | 25 | |
31 | 2016 | Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression | CHIUN HSU ; LIANG-IN LIN ; Cheng, Yu-Che; Feng, Zi-Rui; YU-YUN SHAO ; ANN-LII CHENG ; DA-LIANG OU | Clinical Cancer Research | 43 | 41 | |
32 | 2015 | Consensus development from the 5th asia-pacific primary liver cancer expert meeting (APPLE 2014) | CHIUN HSU ; BANG-BIN CHEN ; CHIEN-HUNG CHEN ; MING-CHIH HO ; CHIA-HSIEN CHENG ; Kokudo N.; Murakami T.; Yeo W.; Seong J.; Jia J.-D.; Han K.-H.; ANN-LII CHENG | Liver Cancer | 17 | 22 | |
33 | 2015 | The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia | HUNG-YANG KUO ; ZHONG-ZHE LIN ; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; YU-YUN SHAO ; CHIUN HSU ; WEN-FANG CHENG ; ANN-LII CHENG ; CHIH-HSIN YANG ; Lai M.-S. | Oncologist | 10 | 10 | |
34 | 2015 | Growth arrest dna damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma | DA-LIANG OU ; Shyue S.-K.; LIANG-IN LIN ; Feng Z.-R.; Liou J.-Y.; Fan H.-H.; Lee B.-S.; CHIUN HSU ; ANN-LII CHENG | Oncotarget | 12 | 9 | |
35 | 2014 | Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: A distinct entity with lower aggressiveness and higher chemosensitivity | SUNG-HSIN KUO ; KUN-HUEI YEH ; Chen L.-T.; CHUNG-WU LIN ; PING-NING HSU ; CHIUN HSU ; MING-SHIANG WU ; Tzeng Y.-S.; Tsai H.-J.; HSIU-PO WANG ; ANN-LII CHENG | Blood Cancer Journal | 34 | 32 | |
36 | 2014 | Strategy for Preventing Hepatitis B Reactivation in Patients With Resolved Hepatitis B Virus Infection After Rituximab-Containing Chemotherapy Reply | CHIUN HSU ; PEI-JER CHEN ; ANN-LII CHENG | Hepatology | 0 | 0 | |
37 | 2014 | Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers | HSIANG-FONG KAO ; I-CHUN CHEN ; CHIUN HSU ; Chang S.-Y.; Chien S.-F.; YEE-CHUN CHEN ; Hu F.-C.; CHIH-HSIN YANG ; ANN-LII CHENG ; KUN-HUEI YEH | Supportive Care in Cancer | 10 | 10 | |
38 | 2014 | Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma | DA-LIANG OU ; Chang C.-J.; YUNG-MING JENG ; Lin Y.-J.; ZHONG-ZHE LIN ; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; CHIUN HSU ; ANN-LII CHENG | Journal of Gastroenterology and Hepatology (Australia) | 11 | 13 | |
39 | 2014 | Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study | CHIUN HSU ; Tsou H.-H.; Lin S.-J.; Wang M.-C.; MING YAO ; Hwang W.-L.; Kao W.-Y.; Chiu C.-F.; Lin S.-F.; Lin J.; Chang C.-S.; HWEI-FANG TIEN ; Liu T.-W.; PEI-JER CHEN ; ANN-LII CHENG | Hepatology | 228 | 210 | |
40 | 2014 | Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer | Ying-Chun Shen ; Li C.-P.; Yen C.-J.; CHIUN HSU ; Lin Y.-L.; ZHONG-ZHE LIN ; Chen L.-T.; Su W.-C.; Chao Y.; KUN-HUEI YEH ; ANN-LII CHENG | Oncology (Switzerland) | 15 | 12 | |
41 | 2014 | Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: The role of survivin | DA-LIANG OU ; Lee B.-S.; LIANG-IN LIN ; Liou J.-Y.; Liao S.-C.; CHIUN HSU ; ANN-LII CHENG | Molecular Cancer | 41 | 33 | |
42 | 2013 | erratum: Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: A meta-analysis and meta-regression (Gastric Cancer (2012) 15(265-280) DOI 10.1007/s10120-011- 0106-5) | CHIUN HSU ; Ying-Chun Shen ; Cheng C.-C.; ANN-LII CHENG ; Hu F.-C.; KUN-HUEI YEH | Gastric Cancer | 0 | 0 | |
43 | 2013 | Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group | Kim S.J.; CHIUN HSU ; Song Y.-Q.; Tay K.; Hong X.-N.; Cao J.; Kim J.S.; Eom H.S.; Lee J.H.; Zhu J.; Chang K.-M.; Reksodiputro A.H.; Tan D.; Goh Y.T.; Lee J.; Intragumtornchai T.; Chng W.-J.; ANN-LII CHENG ; Lim S.T.; Suh C.; Kwong Y.-L.; Kim W.S. | European Journal of Cancer | 98 | 90 | |
44 | 2013 | Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size | ZHONG-ZHE LIN ; Shau W.-Y.; CHIUN HSU ; YU-YUN SHAO ; Yeh Y.-C.; Kuo R.N.-C.; CHIH-HUNG HSU ; CHIH-HSIN YANG ; ANN-LII CHENG ; Lai M.-S. | PLoS ONE | 26 | 24 | |
45 | 2013 | Potentiating the Efficacy of Molecular Targeted Therapy for Hepatocellular Carcinoma by Inhibiting the Insulin-Like Growth Factor Pathway | DA-LIANG OU ; Lee B.-S.; Chang Y.-C.; LIANG-IN LIN ; Liou J.-Y.; CHIUN HSU ; ANN-LII CHENG | PLoS ONE | 10 | 11 | |
46 | 2013 | Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study | CHIH-HUNG HSU ; Kang Y.K.; Yang T.-S.; CHIA-TUNG SHUN ; YU-YUN SHAO ; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; CHIUN HSU ; ANN-LII CHENG | Oncology (Switzerland) | 40 | 41 | |
47 | 2013 | The first two lines of chemotherapy for anthracycline-naive metastatic breast cancer: A comparative study of the efficacy of anthracyclines and non-anthracyclines | WEI-WU CHEN ; DWANG-YING CHANG ; Huang S.-M.; CHING-HUNG LIN ; CHIUN HSU ; Lin M.-H.; CHIUN-SHENG HUANG ; YEN-SHEN LU ; ANN-LII CHENG | Breast | 4 | 5 | |
48 | 2013 | Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma | Ying-Chun Shen ; DA-LIANG OU ; CHIUN HSU ; Lin K.-L.; Chang C.-Y.; CHING-YU LIN ; Liu S.-H.; ANN-LII CHENG | British Journal of Cancer | 155 | 146 | |
49 | 2013 | A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy | YU-YUN SHAO ; PO-CHIN LIANG ; YAO-MING WU ; Huang C.-C.; KAI-WEN HUANG ; CHIA-HSIEN CHENG ; CHIH-HUNG HSU ; CHIUN HSU ; ANN-LII CHENG ; ZHONG-ZHE LIN | Liver International | 15 | 15 | |
50 | 2012 | A Critical Evaluation of the Preventive Effect of Antiviral Therapy on the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C or B: A Novel Approach by Using Meta-Regression | YING-CHUN SHEN ; CHIUN HSU ; Cheng C.-C.; Hu F.-C.; ANN-LII CHENG | Oncology | 34 | 29 | |
51 | 2012 | Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer | LI-CHUN LU ; YU-YUN SHAO ; CHIH-HUNG HSU ; CHIUN HSU ; WEN-FANG CHENG ; YU-LIN LIN ; ANN-LII CHENG ; KUN-HUEI YEH | Anticancer Research | 0 | ||
52 | 2012 | Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study | CHIUN HSU ; Yang T.-S.; Huo T.-I.; Hsieh R.-K.; CHIH-WEI YU ; Hwang W.-S.; Hsieh T.-Y.; Huang W.-T.; Chao Y.; Meng R.; ANN-LII CHENG | Journal of Hepatology | 79 | 74 | |
53 | 2012 | Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy | Kuo Y.-H.; CHING-HUNG LIN ; Shau W.-Y.; Chen T.-J.; SHIH-HUNG YANG ; Huang S.-M.; CHIUN HSU ; YEN-SHEN LU ; ANN-LII CHENG | BMC Cancer | 19 | 16 | |
54 | 2012 | Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma | Shau W.-Y.; YU-YUN SHAO ; Yeh Y.-C.; ZHONG-ZHE LIN ; Kuo R.; CHIH-HUNG HSU ; CHIUN HSU ; ANN-LII CHENG ; Lai M.-S. | Oncologist | 32 | 32 | |
55 | 2012 | Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems | YU-YUN SHAO ; LI-CHUN LU ; ZHONG-ZHE LIN ; CHIUN HSU ; Ying-Chun Shen ; CHIH-HUNG HSU ; ANN-LII CHENG | British Journal of Cancer | 26 | 26 | |
56 | 2012 | Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: A meta-analysis and meta-regression | CHIUN HSU ; Ying-Chun Shen ; Cheng C.-C.; ANN-LII CHENG ; Hu F.-C.; KUN-HUEI YEH | Gastric Cancer | 19 | 18 | |
57 | 2012 | Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma | YU-YUN SHAO ; ZHONG-ZHE LIN ; CHIUN HSU ; Lee, Kuan-Der; Hsiao, Chi-Huang; YEN-SHEN LU ; Huang, Chien-Chung; YING-CHUN SHEN ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncology | 26 | 25 | |
58 | 2012 | Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy | ZHONG-ZHE LIN ; CHIUN HSU ; Hu F.-C.; YU-YUN SHAO ; DWANG-YING CHANG ; CHIH-HSIN YANG ; RUEY-LONG HONG ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncologist | 8 | 10 | |
59 | 2011 | Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil | CHAO-YU HSU ; Ying-Chun Shen ; CHIH-WEI YU ; CHIUN HSU ; Hu F.-C.; CHIH-HUNG HSU ; BANG-BIN CHEN ; Wei S.-Y.; ANN-LII CHENG ; TIFFANY TING-FANG SHIH | Journal of Hepatology | 106 | 100 | |
60 | 2011 | Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials | SHIH-HUNG YANG ; Kuo Y.-H.; YU-WEN TIEN ; CHIUN HSU ; CHIH-HUNG HSU ; SUNG-HSIN KUO ; ANN-LII CHENG | Oncology | 13 | 13 | |
61 | 2011 | Antiangiogenic strategies for the treatment of hepatocellular carcinoma | CHIUN HSU ; Ying-Chun Shen ; ANN-LII CHENG | Targeted Therapies for Hepatocellular Carcinoma | 0 | 0 | |
62 | 2011 | High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy | YU-YUN SHAO ; ZHONG-ZHE LIN ; Chen T.-J.; CHIUN HSU ; Ying-Chun Shen ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncology | 17 | 17 | |
63 | 2011 | Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era | I-CHUN CHEN ; CHING-HUNG LIN ; CHIUN-SHENG HUANG ; HUANG-CHUN LIEN ; CHIUN HSU ; WEN-HUNG KUO ; YEN-SHEN LU ; ANN-LII CHENG | Breast Cancer Research and Treatment | 87 | 74 | |
64 | 2010 | Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma | CHIH-HUNG HSU ; Yang T.-S.; CHIUN HSU ; Toh H.C.; Epstein R.J.; Hsiao L.-T.; PEI-JER CHEN ; ZHONG-ZHE LIN ; Chao T.-Y.; ANN-LII CHENG | British Journal of Cancer | 114 | 112 | |
65 | 2010 | Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma | YU-YUN SHAO ; ZHONG-ZHE LIN ; CHIUN HSU ; Ying-Chun Shen ; CHIH-HUNG HSU ; ANN-LII CHENG | Cancer | 141 | 148 | |
66 | 2010 | Induction of DNA damage-inducible gene GADD45β contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells | DA-LIANG OU ; Ying-Chun Shen ; SUNG-LIANG YU ; Chen K.-F.; Yeh P.-Y.; Fan H.-H.; Feng W.-C.; Wang C.-T.; LIANG-IN LIN ; CHIUN HSU ; ANN-LII CHENG | Cancer Research | 70 | 69 | |
67 | 2010 | Molecular targeted therapy for advanced hepatocellular carcinoma: Current status and future perspectives | Ying-Chun Shen ; CHIUN HSU ; ANN-LII CHENG | Journal of Gastroenterology | 62 | 54 | |
68 | 2010 | Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma | CHIH-HUNG HSU ; Ying-Chun Shen ; ZHONG-ZHE LIN ; PEI-JER CHEN ; YU-YUN SHAO ; Ding Y.-H.; CHIUN HSU ; ANN-LII CHENG | Journal of Hepatology | 110 | 103 | |
69 | 2010 | Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach | Ying-Chun Shen ; CHIUN HSU ; Chen L.-T.; Cheng C.-C.; Hu F.-C.; ANN-LII CHENG | Journal of Hepatology | 124 | 113 | |
70 | 2010 | Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin | YU-YUN SHAO ; KUAN-TING KUO ; Hu F.-C.; YEN-SHEN LU ; CHIUN-SHENG HUANG ; JAU-YU LIAU ; Lee W.-C.; CHIUN HSU ; WEN-HUNG KUO ; KING-JEN CHANG ; CHING-HUNG LIN ; ANN-LII CHENG | Japanese Journal of Clinical Oncology | 28 | 24 | |
71 | 2010 | Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma | Whang-Peng J.; ANN-LII CHENG ; CHIUN HSU ; Chen C.-M. | Journal of Experimental and Clinical Medicine | 25 | 0 | |
72 | 2010 | Geographic difference in survival outcome for advanced hepatocellular carcinoma: Implications on future clinical trial design | CHIUN HSU ; Ying-Chun Shen ; Cheng C.-C.; Hu F.-C.; ANN-LII CHENG | Contemporary Clinical Trials | 41 | 37 | |
73 | 2009 | Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survival | Ying-Chun Shen ; Hu F.-C.; YUNG-MING JENG ; YU-TING CHANG ; ZHONG-ZHE LIN ; MING-CHU CHANG ; CHIUN HSU ; ANN-LII CHENG | Cancer Epidemiology Biomarkers and Prevention | 21 | 20 | |
74 | 2009 | Lamivudine and hepatitis B reactivation | CHIUN HSU ; ANN-LII CHENG ; PEI-JER CHEN | Annals of Internal Medicine | 0 | 0 | |
75 | 2009 | Sorafenib for the treatment of hepatocellular carcinoma across geographic regions | CHIUN HSU ; Ying-Chun Shen ; ANN-LII CHENG | Expert review of Clinical Pharmacology | 10 | 0 | |
76 | 2009 | Strategies to prevent hepatitis B virus reactivation in patients receiving immunosuppressive therapy | CHIUN HSU ; SHU-CHEN WEI ; ANN-LII CHENG ; PEI-JER CHEN | Hepatology | 4 | 3 | |
77 | 2009 | Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway | Chen K.-F.; Yeh P.-Y.; CHIUN HSU ; CHIH-HUNG HSU ; YEN-SHEN LU ; Hsieh H.-P.; PEI-JER CHEN ; ANN-LII CHENG | Journal of Biological Chemistry | 89 | 84 | |
78 | 2009 | The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma | ZHONG-ZHE LIN ; Hsu H.-C.; CHIH-HUNG HSU ; Yeh P.-Y.; Huang C.-Y.F.; Huang Y.-F.; Chen T.-J.; SUNG-HSIN KUO ; CHIUN HSU ; Hu F.-C.; YUNG-MING JENG ; Chung Y.; ANN-LII CHENG | Journal of Hepatology | 39 | 39 | |
79 | 2009 | Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma | DA-LIANG OU ; Ying-Chun Shen ; JA-DER LIANG ; Liou J.-Y.; SUNG-LIANG YU ; Fan H.-H.; Wang D.-S.; YEN-SHEN LU ; CHIUN HSU ; ANN-LII CHENG | Clinical Cancer Research | 32 | 34 | |
80 | 2008 | Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial | CHIUN HSU ; SUNG-HSIN KUO ; Hu F.-C.; ANN-LII CHENG ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHIA-CHI LIN ; Huang T.-C.; PAN-CHYR YANG ; CHIH-HSIN YANG | Lung Cancer | 14 | 11 | |
81 | 2008 | Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment | ZHONG-ZHE LIN ; CHIUN HSU ; YEUN-CHUNG CHANG ; CHONG-JEN YU ; CHIH-HUNG HSU ; CHIA-CHI LIN ; ANN-LII CHENG ; PAN-CHYR YANG ; CHIH-HSIN YANG | Lung Cancer | 5 | 1 | |
82 | 2008 | A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial | CHIUN HSU ; Hsiung C.A.; Su I.-J.; Hwang W.-S.; Wang M.-C.; Lin S.-F.; Lin T.-H.; Hsiao H.-H.; Young J.-H.; Chang M.-C.; Liao Y.-M.; Li C.-C.; Wu H.-B.; HWEI-FANG TIEN ; Chao T.-Y.; Liu T.-W.; ANN-LII CHENG ; PEI-JER CHEN | Hepatology | 273 | 243 | |
83 | 2007 | A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer | CHIA-CHI LIN ; ANN-LII CHENG ; CHIH-HUNG HSU ; YEN-SHEN LU ; CHIUN HSU ; KUN-HUEI YEH ; Wu C.-Y.; CHIUN-SHENG HUANG ; CHIH-HSIN YANG | Anticancer Research | 2 | 2 | |
84 | 2007 | Molecular targeted therapy for advanced hepatocellular carcinoma | Ying-Chun Shen ; CHIUN HSU ; ANN-LII CHENG | Targeted Oncology | 6 | 4 | |
85 | 2007 | Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma | CHIA-CHI LIN ; KUN-HUEI YEH ; CHIH-HSIN YANG ; CHIUN HSU ; YU-CHIEH TSAI ; Hsu W.-L.; ANN-LII CHENG ; CHIH-HUNG HSU | Anti-Cancer Drugs | 10 | 8 | |
86 | 2007 | Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trial | CHIA-CHI LIN ; CHIUN HSU ; CHIH-HUNG HSU ; Hsu W.-L.; ANN-LII CHENG ; CHIH-HSIN YANG | Investigational New Drugs | 105 | 103 | |
87 | 2006 | Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer | Shiah H.-S.; ANN-LII CHENG ; CHIUN HSU ; CHIH-HUNG HSU ; Liu T.-W.; Chang J.-Y.; Jan C.-M.; Chao Y.; Yu W.-L.; Chuang T.-R.; Whang-Peng J.; Chen L.-T. | Journal of Gastroenterology and Hepatology (Australia) | 6 | 5 | |
88 | 2006 | Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer | Ch'ang H.-J.; Wang C.-C.; ANN-LII CHENG ; CHIUN HSU ; YEN-SHEN LU ; MING-CHU CHANG ; Lin J.-T.; HSIU-PO WANG ; Shiah H.-S.; Liu T.-W.; Chang J.-Y.; Whang-Peng J.; Chen L.-T. | Journal of Gastroenterology and Hepatology (Australia) | 8 | 8 | |
89 | 2006 | Difference in the incidence trend of nasopharyngeal and oropharyngeal carcinomas in Taiwan: Implication from age-period-cohort analysis | CHIUN HSU ; Ying-Chun Shen ; Cheng C.-C.; RUEY-LONG HONG ; Chang C.-J.; ANN-LII CHENG | Cancer Epidemiology Biomarkers and Prevention | 67 | 51 | |
90 | 2005 | Effect of thalidomide in hepatocellular carcinoma: Assessment with power Doppler US and analysis of circulating angiogenic factors | CHIUN HSU ; CHIUNG-NIEN CHEN ; Chen L.-T.; Wu C.-Y.; FON-JOU HSIEH ; ANN-LII CHENG | Radiology | 23 | 22 | |
91 | 2005 | Survival of stage IIIB/IV non-small cell lung cancer patients who received chemotherapy but did not participate in clinical trials | SUNG-HSIN KUO ; CHIH-HSIN YANG ; CHONG-JEN YU ; CHIUN HSU ; ANN-LII CHENG ; PAN-CHYR YANG | Lung Cancer | 7 | 7 | |
92 | 2005 | Significant difference in the trends of female breast cancer incidence between Taiwanese and Caucasian Americans: Implications from age-period-cohort analysis | Ying-Chun Shen ; Chang C.-J.; CHIUN HSU ; Cheng C.-C.; Chiu C.-F.; ANN-LII CHENG | Cancer Epidemiology Biomarkers and Prevention | 129 | 116 | |
93 | 2005 | Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer | KUN-HUEI YEH ; YEN-SHEN LU ; CHIH-HUNG HSU ; Lin J.-F.; CHIUN HSU ; SUNG-HSIN KUO ; Li Jr. S.; ANN-LII CHENG | Oncology | 22 | 22 | |
94 | 2004 | Recent advances in non-surgical treatment for advanced hepatocellular carcinoma | CHIUN HSU ; CHIA-HSIEN CHENG ; ANN-LII CHENG | Journal of the Formosan Medical Association | 23 | 18 | |
95 | 2004 | Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma | Lu Y.-S.; CHIUN HSU ; Li C.-C.; Kuo S.-H.; KUN-HUEI YEH ; CHIH-HSIN YANG ; CHIH-HUNG HSU ; Wu C.-Y.; ANN-LII CHENG | Hepato-Gastroenterology | 14 | 13 | |
96 | 2004 | Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract | CHIUN HSU ; Ying-Chun Shen ; CHIH-HSIN YANG ; KUN-HUEI YEH ; YEN-SHEN LU ; CHIH-HUNG HSU ; Liu H.-T.; Li C.-C.; Chen J.-S.; Wu C.-Y.; ANN-LII CHENG | British Journal of Cancer | 42 | 40 | |
97 | 2004 | Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines | Ying-Chun Shen ; CHIUN HSU ; Chen J.-Y.; ANN-LII CHENG | British Journal of Cancer | 4 | 5 | |
98 | 2003 | Low-dose thalidomide treatment for advanced hepatocellular carcinoma | CHIUN HSU ; CHIUNG-NIEN CHEN ; Chen L.-T.; Wu C.-Y.; PEI-MING YANG ; Lai M.-Y.; PO-HUANG LEE ; ANN-LII CHENG | Oncology | 87 | 77 | |
99 | 2003 | Survival-weighted health profile for long-term survivors of acute myelogenous leukemia | CHIUN HSU ; Wang J.-D.; Hwang J.-S.; HWEI-FANG TIEN ; Chang S.-M.; ANN-LII CHENG ; YAO-CHANG CHEN ; JIH-LUH TANG | Quality of Life Research | 28 | 24 | |
100 | 2002 | A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil | CHIH-HUNG HSU ; ANN-LII CHENG ; CHIUN HSU ; CHIH-HSIN YANG ; YEN-SHEN LU ; CHIA-CHI LIN ; Bu C.-F.; KUN-HUEI YEH | Anticancer Research | 12 | 12 | |
101 | 2002 | HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity | CHIUN HSU ; Huang C.-L.; Hsu H.-C.; PO-HUANG LEE ; Wang S.-J.; ANN-LII CHENG | Cancer | 41 | 33 | |
102 | 2002 | Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-na?ve patients with locally advanced or metastatic breast carcinoma | CHIUN HSU ; CHIUN-SHENG HUANG ; Chao T.-Y.; YEN-SHEN LU ; Bu C.-F.; Chen M.M.; KING-JEN CHANG ; ANN-LII CHENG | Cancer | 12 | 11 | |
103 | 2002 | Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer | CHIH-HSIN YANG ; PAN-CHYR YANG ; Wang L.S.; Lee Y.C.; CHIEN-JEN CHANG ; Lui L.T.; Yen S.H.; CHIUN HSU ; ANN-LII CHENG ; Liu M.Y.; Chiang S.C.; Chen Y.M.; KWEN-TAY LUH ; Huang M.H.; Yang P.-C.; Perng R.-P. | British Journal of Cancer | 24 | 20 | |
104 | 2001 | Comparison of MALT and non-MALT primary large cell lymphoma of the stomach: Does histologic evidence of MALT affect chemotherapy response? | CHIUN HSU ; Chen C.-L.; Chen L.-T.; Liu H.-T.; YAO-CHANG CHEN ; Jan C.-M.; Liu C.-S.; ANN-LII CHENG | Cancer | 14 | ||
105 | 2000 | Chemotherapy alone versus, surgery followed by chemotherapy for stage I/IIE large-cell lymphoma of the stomach | Liu H.-T.; CHIUN HSU ; Chen C.-L.; Chiang I.-P.; Chen L.-T.; YAO-CHANG CHEN ; ANN-LII CHENG | American Journal of Hematology | 34 | ||
106 | 1998 | Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL) - A very effective regimen with good patients' compliance for advanced gastric cancer | ANN-LII CHENG ; KUN-HUEI YEH ; Lin J.-T.; CHIUN HSU ; Liu M.-Y. | Anticancer Research | 23 | 20 | |
107 | 1997 | MVP (mitomycin-C, vinblastine, cisplatin) salvage chemotherapy for relapsed and refractory metastatic breast cancer | CHIUN HSU ; KUN-HUEI YEH ; RUEY-LONG HONG ; CHIH-HSIN YANG ; Lin M.-T.; YAO-CHANG CHEN ; ANN-LII CHENG | Journal of the Formosan Medical Association | 4 | 3 |